USA flag logo/image

An Official Website of the United States Government

Novel approaches to extending glucose sensor lifespan

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93738
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DK085957
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AEGIS BIOSCIENCES, LLC
AEGIS BIOSCIENCES, LLC 665 N. RIVERPOINT BLVD SPOKANE, WA 99202
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Novel approaches to extending glucose sensor lifespan
Agency: HHS
Contract: 1R43DK085957-01
Award Amount: $844,788.00
 

Abstract:

DESCRIPTION (provided by applicant): Long term transcutaneous devices such as catheters; require patients to endure extended skin breaches (wounds) that can be difficult to manage clinically, i.e. infection and inflammation. These complications not only sh orten device lifespan, but also compromise patient health. In the case of short-term commercial transcutaneous glucose sensors, FDA has approved their usage for 3-7 days for patients with diabetes. Although infection is an issue with these short-term senso rs extending the in vivo lifespan of these sensors from days to weeks increases the risks of adverse effects. Adverse effects seen at sites of glucose sensor implantation include infection, irritation, redness, itching and inflammation. All these adverse e ffects can and do shorten sensor lifespan in vivo. All these adverse effectives not only compromise sensor function, but also discourage patient involvement in implantable sensors. Clearly, decreasing the risk of infections and inflammation at sensor impla ntation sites would likely not only increase sensor lifespan, but also decrease associated complications and adverse events. In the present proposal we proposed to develop and validate a number of hydrogel based sensor collars and coatings including one th at are bio-enhanced to promote sensor lifespan in vivo. These sensor collars and coatings will be used alone and in combination to extend glucose sensor function in vivo. We believe this approach will usher in a new generation of devices / adjuvants that w ill enhance the function and extend lifespan of not only existing commercial sensors, but also future generation of trancutaneous glucose sensors. PUBLIC HEALTH RELEVANCE: Increasing the implantation time frame beyond the FDA approved 3-7 days for t ranscutaneous glucose sensors increases the risk of adverse effects, such as infection, irritation, redness, itching and inflammation, at sites of sensor implantation and as such decreases sensor lifespan in vivo. In order to avoid these adverse effects we propose to develop and validate a number of hydrogel based sensor collars and coatings including one that are bio-enhanced to promote sensor lifespan in vivo.

Principal Investigator:

David J. Vachon
5092100736
DAVID.VACHON@AEGISBIOSCIENCES.COM

Business Contact:

David J. Vachon
david.vachon@aegisbiosciences.com
Small Business Information at Submission:

AEGIS BIOSCIENCES, LLC
AEGIS BIOSCIENCES, LLC 665 N. RIVERPOINT BLVD SPOKANE, WA 99202

EIN/Tax ID: 621635896
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No